Quote this publication Share Print

PREVYMIS (letermovir), antiviral

Opinions on drugs - Posted on Sep 11 2018

Reason for request


High clinical benefit and minor clinical improvement in the prevention of CMV reactivation and CMV disease after allogeneic haematopoietic stem cell transplantation


  • PREVYMIS has MA for the prevention of cytomegalovirus (CMV) reactivation and CMV disease in adult CMV-seropositive allogeneic haematopoietic stem cell transplantation (HSCT) recipients [R+].

  • It has demonstrated its efficacy, particularly in terms of the reduction of pre-emptive treatment initiation, with no blood toxicity.

  • Its clinical impact on mortality, the incidence of CMV disease or the onset of graft-versus-host disease (GvHD) has yet to be demonstrated.



Actual benefit



Improvement in actual benefit

IV (mineur)